INTRODUCTION
============

Protozoa parasites are composed by a very diverse group of unicellular eukaryotic organism from Protista kingdom, which present nuclei and other structures similar to animals. The main infections in human are due to protozoan of *Plasmodium*, *Trypanosoma*and*Leishmania* genus. Others agents with medical importance exist, such as intestinal protozoa,*Toxoplasma gondii*and *Trichomonas vaginalis*. The protozoan have been characterized as a diverse polyphyletic group that present a wide range of epidemiology characteristics and clinic manifestation in different geographic zones, particularly in tropics and subtropics from developing countries (Table **[1](#T1){ref-type="table"}**) \[[@R1]-[@R4]\].

The diseases caused by protozoan parasite are responsible for considerable mortality and morbidity, affecting more than 500 million of people in the world (Table **[2](#T2){ref-type="table"}**). The history of protozoa infections in humans teaches us that improved nutrition, economic development and public health measures are probably the deciding factors in increasing diseases in the tropics \[[@R4],[@R5]\].

The study of protozoa biology has attracted the attention not only because they are fascinating organism, but also due to the need of finding tools and developing strategies to decrease the remarkable social and economic burden they cause on human societies \[[@R6]\]. The control of protozoan disease requires a complex interplay of activities in the fields of public health, education political will and medical science. However, the epidemiological control of protozoan is unsatisfactory due to difficulties of vector and reservoir control; while the progress in the development of vaccine tends to be slow and arduous. Currently, the chemotherapy remains essential component of both clinical management and disease control programmer in endemic areas \[[@R4]\].

CURRENT DRUGS TO PROTOZOAN DISEASES
===================================

Since the decade of 1930 was discoveries the conventional drugs against protozoa disease, which presents general characteristics such as: (a) the compounds are formed by a low number of elements that including carbon, oxygen and nitrogen; while other elements are only present in specific structures, per example the sulphur; (b) the inorganic compounds are scare, although can be used the arsenic and antimonies; (c) the annular structure are very common and the benzene are present in a high percent of compounds or have nitrogen; (d) the methyl, hydroxyl and amine group are very frequently; while the sulphydryl radical is absent \[[@R7]\]. Current drugs in use as anti-protozoan agents were discovered over 50 years. A number of factors limit the utility of existing drugs (Table **[3](#T3){ref-type="table"}**) in resource-poor setting, such as high cost, poor compliance, drug resistance, low efficacy and poor safety \[[@R1],[@R2],[@R5]\].

DRUG DEVELOPMENT TO PROTOZOAN DISEASES
======================================

There is still a great need for drug development against protozoan diseases. The past 20 years has seen a significant increase in our basic knowledge of protozoa parasite. The currently search to develop new drugs have been facilitated by advances in sciences, especially in the field of parasite genomics (identification of unique metabolic pathways and key enzyme of the protozoa), chemistry methodologies (high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) and mass spectrometry) and bioinformatics tools (quantitative structure-activity relation ship (QSAR) modeling techniques) \[[@R8]-[@R12]\]. In parallel, recent development have been increased thanks to dedicated academic, public initiatives, private-public partnerships, pharmaceutical industry and the experience of public health care organizations that focus on various aspects of drug discovery for infectious diseases, including the injection of new funds into this research area \[[@R13],[@R14]\]. Different strategies have been defined to develop new anti-protozoan drugs in short/medium time (optimization of therapy with existing drugs, development of analogs of current drugs, combination therapy with conventional drugs and identification of agents to use against other indications) and in large time (search new targets and rational drug design and natural products) \[[@R15]\].

This special issue of *The Open Medicinal Chemistry Journal* will present some of developments in this field with the aim to shown the significant advances in the discovery of new anti-protozoan drugs

###### 

General Features of Main Protozoan Parasitic Diseases that Affect the Human Health

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease                   Some Representative Etiological Agents                                                      Geographical Localization                         Clinical Features
  ------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Malaria                   *Plasmodium falciparum, P. vivax*                                                           Over 100 countries in the tropic and subtropics   Fever, shivering, cough, respiratory distress, pain in the joints, headache, watery diarrhea, vomiting, convulsions severe anemia

  African trypanosomiasis   *Trypanosoma brucei*                                                                        36 countries in sub-Sahara Africa                 Initial haemolytic phase (fever, joint pains followed by neurological disorder, somnolence

  Chagas disease            *Trypanosoma cruzi*                                                                         From northem Mexico to South Argentina            Acute phase (fever and splenomegaly)\
                                                                                                                                                                          Chronic phase (irreversible damage to heart, esophagus and colon)

  Leishmaniasis             *Leishmania donovani, L. major, L. mexicana, L. braziliensis*                               Over 88 countries in tropic and subtropics        Skin ulcers, mucocutaneous complications and visceral diseases (hepatosplenomegaly)

  Toxoplasmosis             *Toxoplasma gondii*                                                                         Worldwide                                         Blindness and mental retardation can result in congenitally infected children.\
                                                                                                                                                                          Immunosuppressed patients can present more severe symptoms: splenomegaly, polymyositis, dermatomyositis, chorioretinitis, myocarditis, pneumonitis, hepatitis, encephalitis, and multisystem organ failure.

  Trichomoniasis            *Trichomonas vaginalis*                                                                     Worldwide                                         Vaginal discharge, odor and edema or erythema.

  Intestinal protozoan      *Giardia lamblia, Entamoeba histolytica, Cryptosporidium parvum, Cyclospora cayetanensis*   Worldwide                                         Hematuria, anemia, impaired growth. Renal, hepatic and spleen failure
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of Statistics for Damage Caused by Main Parasitic Diseases

  Disease                   Population at Risk (x10^6^)   Number of People Infected (x10^6^)   Number of Death (x10^3^)
  ------------------------- ----------------------------- ------------------------------------ --------------------------
  Malaria                   \~ 2 000                      \~ 300                               \~1000-2000
  African trypanosomiasis   \~ 60                         \~ 0.3-0.5                           \~ 50
  Chagas disease            \~ 40                         \~ 17                                \~ 21
  Leishmaniasis             \~ 350                        \~ 2                                 \~ 59
  Intestinal protozoans     \> 1000                       \~ 450                               \~ 40-100

###### 

Limitations of Currently Used Drugs for Main Protozoan Diseases

  Disease                          Some Current Used Drugs                                                Limitations
  -------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------------
  Malaria                          Chloroquine, 1945                                                      Resistance
  Artemisin, 1994                  Compliance, cost, manufacture                                          
  African trypanosomiasis          Suramin, 1920                                                          Safety, not effective in late-stage diseases, injectable
  Pentamidine, 1939                Safety, resistance, not effective in late-stage diseases, injectable   
  Melarsoprol, 1949                Safety, resistance, injectable                                         
                                   Eflornithine, 1991                                                     Cost, injectable, only effective against *T. gambiense*
  Chagas disease                   Nifurtimox, 1970                                                       Safety, long treatment, compliance, activity limited to acute stage of disease
  Benznidazole, 1974               Safety                                                                 
  Leishmaniasis                    Pentamidine, 1939                                                      Safety, resistance, injectable
  Antimonials, 1950                Safety, resistance, injectable                                         
  Liposomal amphotericin B, 1990   Cost, injectable                                                       
  Miltefosine, 2002                Contraindicated in pregnancy                                           
  Toxoplasmosis                    Sulfonamides, 1932                                                     Safety, only in combined therapy
  Pyrimethamine, 1951              Safety, Contraindicated in pregnancy                                   
  Trichomoniasis                   Metronidazole, 1955                                                    Resistance
  Intestinal protozoan             Metronidazole, 1955                                                    Resistance
  Diloxanide, 1956                 Resistance                                                             
